The Degree of Albuminuria Is Related to Left Ventricular Hypertrophy in Hypertensive Diabetics and Is Associated with Abnormal Left Ventricular Filling: A Pilot Study

Angiology

Volumn 54, Issue 6, 2003, Pages 671-678

  Salmasi, Abdul Majeed ^a   Jepson, Ewart ^a   Grenfell, Ana ^a   Kirollos, Camelia ^a   Dancy, Mark ^a  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; MALE; PREDICTION; PROTEINURIA; STRESS ECHOCARDIOGRAPHY;

EID: 0344011585     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400606     Document Type: Article

References (50)

1. Fuller JH, Stevens LK, Wang SL: International variations in cardiovascular mortality associated with diabetes mellitus: The WHO multinational study of vascular diseases in diabetes. Ann Med 28:319-322, 1996.
2. Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham study. JAMA 241:2035-2038, 1979.
3. Stamler J, Vaccaro O, Neaton JD, et al: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993.
4. Turner RC, Millns H, Neil HAW, et al: Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828, 1998.
5. Moss SE, Klein R, Klein BEK, et al: The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154:2473-2479, 1994.
6. Jarrett RJ, Viberti GC, Argyropoulos A, et al: Microalbuminuria predicts mortality in non-insulin dependent diabetes. Diabetic Med 1:17-19, 1984.
7. Gerstein HC, Mann JFE, Yi Q, et al: Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001.
8. Goldbourt U, Yaari S, Medalie JH: Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. Cardiology 82:100-121, 1993.
9. Damsgaard EM, Froland A, Jorgensen OD, et al: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300:297-300, 1990.
10. Agewall S, Wikstrand J, Ljungman S, et al, for the Risk Factor Intervention Study Group: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 80:164-169, 1997.
11. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 157:1413-1418, 1997.
12. Grenfell A, Monaghan M, Watkins PJ, et al: Cardiac hypertrophy in diabetic nephropathy: An echocardiographic study. Diabetic Med 5:840-844, 1988.
13. Sampson MJ, Chambers J, Sprigings D, et al: Intraventricular septal hypertrophy in type 1 diabetic patients with microalbuminuria or early proteinuria. Diabetic Med 7:126-131, 1990.
14. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 141:334-341, 2001.
15. Mosterd A, D'Agostino RB, Silbershatz H, et al: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 340:1221-1227, 1999.
16. Grandi AM, Santillo R, Bertolini A, et al: Microalbuminuria as a marker of preclinical abnormal filling in never-treated essential hypertension. Am J Hypertens 14:644-648, 2001.
17. Vecht RJ: The grip test: A simple method for the assessment of left ventricular performance. Eur J Cardiol 4:335-347, 1976.
18. Krayenbuehl HP, Rutishauser W, Schoenbeck M, et al: Evaluation of left ventricular function from isovolumic pressure measurements during isometric exercise. Am J Cardiol 29:323-330, 1972.
19. Nishimura RA, Tajik J: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta stone. J Am Coll Cardiol 30:8-18, 1997.
20. Helack JW, Reichek N: Quantitation of human left ventricular mass and volume by two-dimensional echocardiography: In vitro validation. Circulation 63:1398-1407, 1981.
21. Byrd BF, Finkbeiner W, Bouchard A, et al: Accuracy and reproducibility of clinically acquired two-dimensional echocardiographic mass measurements. Am Heart J 117:133-137, 1989.
22. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57:450-458, 1986.
23. Folland ED, Parisi AF, Moynihan PF, et al: Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison cineangiographic and radionuclide techniques. Circulation 60:760-766, 1979.
24. Hamby RI, Zoneraich S, Sherman S: Diabetic cardiomyopathy. JAMA 229:1749-1754, 1974.
25. Wachtell K, Olsen MH, Dahlof B, et al: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. J Hypertens 20:405-407, 2002.
26. Post WS, Blumenthal RS, Weiss JL, et al: Spot urinary albumin-creatinine ratio predicts left ventricular hypertrophy in young hypertensive African-American men. Am J Hypertens 13:1168-1172, 2000.
27. Mbanya JC, Sobngwi E, Mbanya DS, et al: Left ventricular mass and systolic function in African diabetic patients: Association with microalbuminuria. Diabetes Metab 27:378-382, 2001.
28. Earle KA, Mishra M, Morocutti A, et al: Microalbuminuria as a marker of silent myocardial ischaemia in IDDM patients. Diabetologia 39:854-856, 1996.
29. Shapiro LM, McKenna WJ: Left ventricular hypertrophy: Relation of structure to diastolic function in hypertension. Br Heart J 51:637-642, 1984.
30. Kapuku GK, Seto S, Mori H, et al: Impaired left ventricular filling in borderline hypertensive patients without cardiac structural changes. Am Heart J 125:1710-1716, 1993.
31. Salmasi AM, Alimo A, Jepson E, et al: Age-associated changes in left ventricular diastolic function are related to increasing left ventricular mass. Am J Hypertens 16:473-477, 2003.
32. Strauer BE, Motz W, Vogt M, et al: Impaired coronary flow reserve in NIDDM: A possible role for diabetic cardiopathy in humans. Diabetes 46(suppl 2):S119-S124, 1997.
33. Gotzsche O, Darwish A, Gotzsche L, et al: Incipient cardiomyopathy in young insulin-dependent diabetic patients: A seven-year prospective Doppler echocardiographic study. Diabet Med 13:834-840, 1996.
34. Galderisi M, Anderson KM, Wilson PWF, et al: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham heart study). Am J Cardiol 68:85-89, 1991.
35. Felicio JS, Ferreira SRG, Plavnik FL: Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens 13:1149-1154, 2000.
36. Stehouwer CD, Nauta JJ, Zeldenrust GC, et al: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319-323, 1992.
37. Giaconi S, Ievanti C, Fommei E, et al: Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens 2:259-261, 1989.
38. Hoogeveen EK, Kostense PJ, Jager A, et al: Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn study. Kidney Int 54:203-209, 1998.
39. Niskanen L, Turpeinen A, Penttila I, et al: Hyperglycemia and compositional lipoprotein abnormalities are predictors of cardiovascular mortality in type 2 diabetes: A 15-year follow-up from the time of diagnosis. Diabetes Care 21:1861-1869, 1998.
40. Forsblom CM, Groop PH, Ekstrand A, et al: Predictors of progression from normalbuminuria to microalbuminuria in NIDDM. Diabetes Care 21:1932-1938, 1998.
41. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001.
42. Brenner BM, Cooper ME, De Zeeuw, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001.
43. Parving H-H, Lenhert H, Bronchner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001.
44. Lindholm LH, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:1004-1010, 2002.
45. Papadakis JA, Milionis HJ, Press M, et al: Treating dyslipidaemia in non-insulin dependent diabetes mellitus-a special reference to statins. J Diabetes Complic 15:211-226, 2001.
46. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 53:493-502, 2002.
47. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001.
48. Youssef F, Seifalian AM, Jagroop A, et al: The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23:358-364, 2002.
49. Su SF, Hsiao CL, Chu CW, et al: Effects of pravastatin on left ventricular mass in patients with hyperlipidaemia and essential hypertension. Am J Cardiol 86:514-518, 2000.
50. Kalogeropoulou K, Mortzos G, Migdalis I, et al: Carotid atherosclerosis in type 2 diabetes mellitus: Potential role of endothelin-1, lipoperoxides and prostacyclin. Angiology 53:279-285, 2002.